ClinicalTrials.gg
Not yet recruitingNCT07951099QOCPITUpdated Nov 20, 2026

Quality Of Life in Prostate Cancer Patients Initiating Triptorelin

An observational study in Prostate Cancer, sponsored by Ipsen. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Ipsen · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
819
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 27 studies in Prostatic Neoplasms by Ipsen — 1 open to participants now, 1 under way, none of them phase 3. Prostatic Neoplasms · Ipsen.

Planned enrollment
3rd of 11
819 · median 510
Started
2026
the only one that year
Observational
11 of 27
1 open now
Registered
27th of 27
by date

Among the 27 studies in Prostatic Neoplasms by Ipsen, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2026, is one of 11 observational ones, and was the 27th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 27 studies in Prostatic Neoplasms by Ipsen is open now.

Who these studies take

Of the 1,234 Prostatic Neoplasms studies recruiting now, 932 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Prostatic Neoplasms by Ipsen, or all of them as a file.
02

Study summary

Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.

The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.

Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.

This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.

Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible to be included in the study only if all the following criteria apply:

  1. Males ≥18 years old.
  2. Patient with confirmed PCa.
  3. Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
  4. Patient able to understand and complete study-related questionnaires.
  5. Patient having been informed and not opposed to participating in the study.
  6. Patient covered by healthcare insurance.

Exclusion criteria

Exclusion Criteria

Patients will not be included in the study if they meet any of the following criteria:

  1. Patient currently participating in any interventional clinical trial.
  2. Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
  3. Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
819 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score

    Time frame: At 6 months

Secondary outcomes

  1. Participants' baseline demographic characteristics

    Including: * Age. * Partnership status. * Employment status. * Area of residence. * Socioeconomic status.

    Time frame: At baseline

  2. Participants' clinical characteristics at baseline

    Including: * BMI * Eastern Cooperative Oncology Group (ECOG) Performance status score. * G8 score if applicable. * Comorbidity status, medical and surgical history, and systemic treatments for comorbidities. * Participant's level of physical activity, using IPAQ questionnaire.

    Time frame: At baseline

  3. Prostate cancer characteristics at diagnosis and baseline

    Including: * Prostate Cancer (PCa) presentation (new diagnosis or recurrence/progression) at baseline. * Gleason score/International Society of Urological Pathology (ISUP) group * TNM (Tumor Node Metastasis) at diagnosis. * Prostate Specific Antigen (PSA) and testosterone levels at PCa diagnosis. * Previous treatments received for PCa, if any.

    Time frame: At baseline

  4. Participants symptoms at baseline

    Time frame: At baseline

  5. Participants' PCa treatment patterns at baseline

    * Triptorelin treatment modalities * Radiotherapy modalities * Associated systemic PCa treatments

    Time frame: At baseline

  6. Participants' healthcare pathway/supportive care done or planned

    Including: * Pretreatment assessments * Visits to supportive health care professionals done or planned. * Participation in a dedicated healthcare pathway (as a one-day hospital stay with visits to several healthcare professionals). * Associated prescriptions or recommendations * Complementary information on cancer patient organizations and/or websites.

    Time frame: At baseline

  7. Evolution of PCa at 6-month follow-up according to investigator's opinion

    Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression.

    Time frame: At 6 months

  8. Symptoms and biological characteristics at 6 months

    Time frame: At 6 months

  9. Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire

    The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity.

    Time frame: At 6 months

  10. Participants' Quality Of life (QoL)

    * FACT-P total score, sub-scores and individual items, at baseline and at 6- month follow-up, and their changes from baseline. * European Organisation for Research and Treatment of CancerQuality-of-Life Questionnaire Prostate Module (EORTC QLQ-PR25) sexual activity individual items and domain scores at baseline and at 6-month follow-up and changes from baseline.

    Time frame: At baseline and at 6 months

  11. Participants' PCa treatment patterns at 6 months

    * Collection of triptorelin administrations from initiation * Radiotherapy modalities in case of changes, * Associated systemic PCa treatments in case of changes.

    Time frame: At baseline and at 6 months

  12. Participants' healthcare pathway/supportive care at 6 months

    • Participant's healthcare pathway/type of supportive care in case of changes.

    Time frame: At 6 months

  13. Identification of factors associated with participant's quality of life

    • Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: \]-3;3\[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model.

    Time frame: At 6 months

  14. Percentage of participants with adverse events

    An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up.

    Time frame: From enrollment to Month 6

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2028, 15 months later.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 15 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 29 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Nov 23, 2026
Primary completionEst.
Feb 25, 2028
CompletionEst.
Oct 30, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951099
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Nov 23, 2026 (estimated)
Primary completion
Feb 25, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Ipsen Clinical Study Enquiries
Contact
clinical.trials@ipsen.com
See email
Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion